Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Arcturus Therapeutics

Arcturus Therapeutics Receives Clearance of an Investigational New Drug Application to U.S. Food and Drug Administration for ARCT-032, an Investigational Inhaled mRNA Therapeutic to Treat Cystic Fibrosis
From Arcturus Therapeutics
Via Business Wire
Tickers ARCT
Nature Communications Publishes Pivotal Data Demonstrating Efficacy and Tolerability of CSL and Arcturus Therapeutics’ COVID-19 Vaccine
From Arcturus Therapeutics
Via Business Wire
Tickers ARCT ASX:CSL CSLLY OTC
New COVID-19 sa-mRNA Results from CSL and Arcturus Therapeutics Demonstrate Longer Duration of Immunity Compared to Conventional COVID-19 mRNA Vaccine Booster
From Arcturus Therapeutics
Via Business Wire
Tickers ARCT ASX:CSL CSLLY OTC
CSL and Arcturus Therapeutics’ ARCT-154 Demonstrates Non-Inferiority to Original Strain and Superior Immunogenicity to Omicron BA.4/5 Variant Compared to First-Generation mRNA Vaccine Booster
From Arcturus Therapeutics
Via Business Wire
Tickers ARCT ASX:CSL CSLLY OTC
Arcturus Therapeutics to Attend Upcoming Investor Conferences
From Arcturus Therapeutics
Via Business Wire
Tickers ARCT
Arcturus Therapeutics Joint Venture mRNA Manufacturing Partner, ARCALIS, Awarded $115 Million in Grants from the Japanese Government
From Arcturus Therapeutics
Via Business Wire
Tickers ARCT
Arcturus Therapeutics to Report First Quarter 2022 Financial Results and Provide Corporate Update on May 9, 2022
From Arcturus Therapeutics
Via Business Wire
Tickers ARCT
Arcturus Therapeutics to Report Fourth Quarter and Year-End 2021 Financial Results and Provide Corporate Update on February 28, 2022
From Arcturus Therapeutics
Via Business Wire
Tickers ARCT
Arcturus Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Arcturus Therapeutics
Via Business Wire
Tickers ARCT
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.